Vaccine Adjuvants Market
PUBLISHED: 2024 ID: SMRC26420
SHARE
SHARE

Vaccine Adjuvants Market

Vaccine Adjuvants Market Forecasts to 2030 - Global Analysis By Adjuvant Type (Alum (Aluminum Hydroxide), Liposomes, Viral-Derived Particles (VDPs) and Other Adjuvants Types), Disease Type (Infectious Diseases, Cancer and Other Disease Types), Vaccine Type, Route of Administration, Application, End User and By Geography

4.9 (49 reviews)
4.9 (49 reviews)
Published: 2024 ID: SMRC26420

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $0.8 billion in 2024 and is expected to reach $1.4 billion by 2030 growing at a CAGR of 8.9% during the forecast period. Vaccine adjuvants are substances added to vaccines to enhance the immune response to the vaccine antigen. They help create a stronger and longer-lasting immune response, reducing the amount of antigen needed and the number of doses required for immunity. Adjuvants can be immunostimulants that activate the immune system or delivery systems that present the antigen more effectively to immune cells.

According to a report by the World Health Organization (WHO), the global human vaccine market grew from USD 6 billion in 2000 to USD 33 billion in 2014 and USD 36.45 billion in 2018, with sales to high-income countries representing about 65% of the total value.

Market Dynamics:

Driver: 

Rising prevalence of infectious diseases

As the global burden of infectious diseases continues to grow, there is an increasing demand for effective vaccines to prevent and control these diseases. Adjuvants play a crucial role in enhancing the immunogenicity and efficacy of vaccines, making them more potent and long-lasting. The high incidence rates of infectious diseases such as influenza, malaria, tuberculosis, and emerging pathogens like COVID-19 have further accelerated the need for adjuvanted vaccines. Consequently, the growing prevalence of infectious diseases is propelling the demand for vaccine adjuvants and driving market growth.

Restraint:

High cost of development and manufacturing

The high cost of developing and manufacturing vaccine adjuvants is a significant restraint in the market. The development process is complex, time-consuming, and requires substantial investment in research and development, production facilities, and specialized knowledge. Vaccine development can take a few years, and it comes at a high cost. The high failure rate makes it challenging for manufacturers to secure funds and cover operational expenses.

Opportunity:

Development of new vaccines

As researchers work on vaccines for challenging diseases like HIV, malaria, and cancer, there is a growing need for potent adjuvants to enhance the efficacy of these vaccines. Novel adjuvants can help stimulate stronger and more targeted immune responses, reduce the amount of antigen required, and enable the use of new vaccine delivery methods. Ongoing research into adjuvants such as saponins, TLR agonists, nanoparticles, and mucosal adjuvants holds promise for the development of more effective and innovative vaccines. The increasing demand for new and improved vaccines is expected to drive the growth of the vaccine adjuvant market in the coming years.

Threat:

Stringent regulatory requirements

Stringent regulatory requirements pose a significant threat to the market due to the lengthy and costly approval processes for new adjuvants. Meeting stringent safety and efficacy standards set by regulatory authorities such as the FDA and EMA requires extensive preclinical and clinical data, prolonging product development timelines. Additionally, any regulatory hurdles or delays in approvals can hinder market entry and limit innovation. Adhering to complex regulatory frameworks adds financial burden and uncertainty for companies, impacting their competitiveness and market growth.

Covid-19 Impact: 

The COVID-19 pandemic had a positive impact on the vaccine adjuvants market. The urgent need for effective vaccines drove advancements in adjuvant technologies as researchers explored various formulations to enhance immune responses against the virus. This led to increased demand for adjuvants during the pandemic, with the trend expected to persist in the coming years. The crisis accelerated innovations and discoveries in adjuvants that have broader implications for future vaccine development.

The infectious diseases segment is expected to be the largest during the forecast period

The infectious diseases segment is expected to be the largest in the vaccine adjuvants market during the forecast period due to the rising incidence of infectious diseases globally and the urgent need for effective vaccines. Increasing government initiatives and funding for immunization programs, coupled with advancements in adjuvant technology enhancing vaccine efficacy, are driving this growth. Furthermore, heightened awareness of infectious disease prevention and the ongoing development of vaccines targeting emerging pathogens contribute to the dominance of this segment.

The intramuscular segment is expected to have the highest CAGR during the forecast period 

The intramuscular segment is expected to have the highest CAGR in the vaccine adjuvants market during the forecast period. This is because intramuscular injection is the most common method of vaccine administration, as it allows for efficient delivery of the vaccine to the muscle tissue, which has a rich blood supply and contains immune cells that can quickly respond to the vaccine. Intramuscular administration also reduces the risk of local reactions compared to subcutaneous or intradermal routes. Furthermore, many vaccines containing adjuvants are strongly preferred to be administered intramuscularly to optimize immunogenicity and minimize adverse reactions.

Region with largest share:

The Asia Pacific is projected to hold the highest market share in the vaccine adjuvant market due to its large population, increasing prevalence of infectious diseases, and rising awareness about vaccination benefits. Additionally, government initiatives and investments in healthcare infrastructure, coupled with the presence of key market players and an expanding biopharmaceutical industry, contribute to market growth. The region's focus on innovative research and development, along with favorable regulatory environments, further drives the demand for vaccine adjuvants in Asia Pacific region.

Region with highest CAGR:

North America is expected to exhibit the highest CAGR in the vaccine adjuvants market during the forecast period due to advanced healthcare infrastructure, robust R&D activities, and significant investments in vaccine development. The region benefits from strong government support, favorable regulatory frameworks, and a high prevalence of infectious diseases, driving the demand for effective vaccines. Additionally, the presence of leading biopharmaceutical companies and increasing awareness about vaccination's importance contribute to the rapid market growth in North America.

Key players in the market

Some of the key players in Vaccine Adjuvants Market include GlaxoSmithKline plc (GSK), CSL Limited, Novavax, Inc., SPI Pharma, Inc., Seppic (Air Liquide), Invivogen, Croda International Plc, Dynavax Technologies Corporation, Adjuvance Technologies Inc., Agenus Inc., OZ Biosciences, Avanti Polar Lipids, Inc., MVP Laboratories, Inc., Vaxine Pty Ltd, GlycoMira Therapeutics Inc., Pfizer Inc., Sanofi Merck & Co., Inc., Zoetis Inc. and Moderna, Inc.

Key Developments:

In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize Novavax's COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines. The deal allows Sanofi to use Novavax's COVID-19 shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products.

In October 2023, SPI Pharma, Inc. signed a distribution partnership with Q-Vant Biosciences, Inc. The partnership involves the development of Q-Vant's Q-SAP saponin adjuvant technology. The partnership would provide saponin adjuvants to vaccine developers and manufacturers globally.

In July 2023, CSL Seqirus, a business of CSL announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company is positioned to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.

Adjuvants Types Covered:
• Alum (Aluminum Hydroxide)
• Liposomes
• Viral-Derived Particles (VDPs)
• Emulsions
• Carbohydrate Adjuvants
• Tensoactive Adjuvants 
• Organic Adjuvants
• Mineral Salt-Based Adjuvants
• Other Adjuvants Types

Disease Types Covered:
• Infectious Diseases
• Cancer
• Other Disease Types

Vaccine Types Covered:
• Viral Vaccines
• Bacterial Vaccines
• Parasitic Vaccines
• Other Vaccine Types

Route of Administration Covered:
• Intramuscular
• Subcutaneous
• Intranasal
• Oral
• Intradermal

Applications Covered:
• Research Application
• Commercial Application

End Users Covered:
• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary      
       
2 Preface      
 2.1 Abstract     
 2.2 Stake Holders     
 2.3 Research Scope     
 2.4 Research Methodology     
  2.4.1 Data Mining    
  2.4.2 Data Analysis    
  2.4.3 Data Validation    
  2.4.4 Research Approach    
 2.5 Research Sources     
  2.5.1 Primary Research Sources    
  2.5.2 Secondary Research Sources    
  2.5.3 Assumptions    
       
3 Market Trend Analysis      
 3.1 Introduction     
 3.2 Drivers     
 3.3 Restraints     
 3.4 Opportunities     
 3.5 Threats     
 3.6 Application Analysis     
 3.7 End User Analysis     
 3.8 Emerging Markets     
 3.9 Impact of Covid-19     
       
4 Porters Five Force Analysis      
 4.1 Bargaining power of suppliers     
 4.2 Bargaining power of buyers     
 4.3 Threat of substitutes     
 4.4 Threat of new entrants     
 4.5 Competitive rivalry     
       
5 Global Vaccine Adjuvants Market, By Adjuvant Type      
 5.1 Introduction     
 5.2 Alum (Aluminum Hydroxide)     
 5.3 Liposomes     
 5.4 Viral-Derived Particles (VDPs)     
 5.5 Emulsions     
 5.6 Carbohydrate Adjuvants     
 5.7 Tensoactive Adjuvants   
 5.8 Organic Adjuvants     
 5.9 Mineral Salt-Based Adjuvants     
 5.10 Other Adjuvants Types     
       
6 Global Vaccine Adjuvants Market, By Disease Type      
 6.1 Introduction     
 6.2 Infectious Diseases     
 6.3 Cancer     
 6.4 Other Disease Types     
       
7 Global Vaccine Adjuvants Market, By Vaccine Type      
 7.1 Introduction     
 7.2 Viral Vaccines     
 7.3 Bacterial Vaccines     
 7.4 Parasitic Vaccines     
 7.5 Other Vaccine Types     
       
8 Global Vaccine Adjuvants Market, By Route of Administration      
 8.1 Introduction     
 8.2 Intramuscular     
 8.3 Subcutaneous     
 8.4 Intranasal     
 8.5 Oral     
 8.6 Intradermal     
       
9 Global Vaccine Adjuvants Market, By Application      
 9.1 Introduction     
 9.2 Research Application     
 9.3 Commercial Application     
       
10 Global Vaccine Adjuvants Market, By End User      
 10.1 Introduction     
 10.2 Human Vaccine Adjuvants     
 10.3 Veterinary Vaccine Adjuvants     
       
11 Global Vaccine Adjuvants Market, By Geography      
 11.1 Introduction     
 11.2 North America     
  11.2.1 US    
  11.2.2 Canada    
  11.2.3 Mexico    
 11.3 Europe     
  11.3.1 Germany    
  11.3.2 UK    
  11.3.3 Italy    
  11.3.4 France    
  11.3.5 Spain    
  11.3.6 Rest of Europe    
 11.4 Asia Pacific     
  11.4.1 Japan    
  11.4.2 China    
  11.4.3 India    
  11.4.4 Australia    
  11.4.5 New Zealand    
  11.4.6 South Korea    
  11.4.7 Rest of Asia Pacific    
 11.5 South America     
  11.5.1 Argentina    
  11.5.2 Brazil    
  11.5.3 Chile    
  11.5.4 Rest of South America    
 11.6 Middle East & Africa     
  11.6.1 Saudi Arabia    
  11.6.2 UAE    
  11.6.3 Qatar    
  11.6.4 South Africa    
  11.6.5 Rest of Middle East & Africa    
       
12 Key Developments      
 12.1 Agreements, Partnerships, Collaborations and Joint Ventures     
 12.2 Acquisitions & Mergers     
 12.3 New Product Launch     
 12.4 Expansions     
 12.5 Other Key Strategies     
       
13 Company Profiling      
 13.1 GlaxoSmithKline plc (GSK)     
 13.2 CSL Limited     
 13.3 Novavax, Inc.     
 13.4 SPI Pharma, Inc.     
 13.5 Seppic (Air Liquide)     
 13.6 Invivogen     
 13.7 Croda International Plc     
 13.8 Dynavax Technologies Corporation     
 13.9 Adjuvance Technologies Inc.     
 13.10 Agenus Inc.     
 13.11 OZ Biosciences     
 13.12 Avanti Polar Lipids, Inc.     
 13.13 MVP Laboratories, Inc.     
 13.14 Vaxine Pty Ltd     
 13.15 GlycoMira Therapeutics Inc.     
 13.16 Pfizer Inc.     
 13.17 Sanofi     
 13.18 Merck & Co., Inc.     
 13.19 Zoetis Inc.     
 13.20 Moderna, Inc.     
       
List of Tables       
1 Global Vaccine Adjuvants Market Outlook, By Region (2022-2030) ($MN)      
2 Global Vaccine Adjuvants Market Outlook, By Adjuvant Type (2022-2030) ($MN)      
3 Global Vaccine Adjuvants Market Outlook, By Alum (Aluminum Hydroxide) (2022-2030) ($MN)      
4 Global Vaccine Adjuvants Market Outlook, By Liposomes (2022-2030) ($MN)      
5 Global Vaccine Adjuvants Market Outlook, By Viral-Derived Particles (VDPs) (2022-2030) ($MN)      
6 Global Vaccine Adjuvants Market Outlook, By Emulsions (2022-2030) ($MN)      
7 Global Vaccine Adjuvants Market Outlook, By Carbohydrate Adjuvants (2022-2030) ($MN)      
8 Global Vaccine Adjuvants Market Outlook, By Tensoactive Adjuvants (2022-2030) ($MN)      
9 Global Vaccine Adjuvants Market Outlook, By Organic Adjuvants (2022-2030) ($MN)      
10 Global Vaccine Adjuvants Market Outlook, By Mineral Salt-Based Adjuvants (2022-2030) ($MN)      
11 Global Vaccine Adjuvants Market Outlook, By Other Adjuvants Types (2022-2030) ($MN)      
12 Global Vaccine Adjuvants Market Outlook, By Disease Type (2022-2030) ($MN)      
13 Global Vaccine Adjuvants Market Outlook, By Infectious Diseases (2022-2030) ($MN)      
14 Global Vaccine Adjuvants Market Outlook, By Cancer (2022-2030) ($MN)      
15 Global Vaccine Adjuvants Market Outlook, By Other Disease Types (2022-2030) ($MN)      
16 Global Vaccine Adjuvants Market Outlook, By Vaccine Type (2022-2030) ($MN)      
17 Global Vaccine Adjuvants Market Outlook, By Viral Vaccines (2022-2030) ($MN)      
18 Global Vaccine Adjuvants Market Outlook, By Bacterial Vaccines (2022-2030) ($MN)      
19 Global Vaccine Adjuvants Market Outlook, By Parasitic Vaccines (2022-2030) ($MN)      
20 Global Vaccine Adjuvants Market Outlook, By Other Vaccine Types (2022-2030) ($MN)      
21 Global Vaccine Adjuvants Market Outlook, By Route of Administration (2022-2030) ($MN)      
22 Global Vaccine Adjuvants Market Outlook, By Intramuscular (2022-2030) ($MN)      
23 Global Vaccine Adjuvants Market Outlook, By Subcutaneous (2022-2030) ($MN)      
24 Global Vaccine Adjuvants Market Outlook, By Intranasal (2022-2030) ($MN)      
25 Global Vaccine Adjuvants Market Outlook, By Oral (2022-2030) ($MN)      
26 Global Vaccine Adjuvants Market Outlook, By Intradermal (2022-2030) ($MN)      
27 Global Vaccine Adjuvants Market Outlook, By Application (2022-2030) ($MN)      
28 Global Vaccine Adjuvants Market Outlook, By Research Application (2022-2030) ($MN)      
29 Global Vaccine Adjuvants Market Outlook, By Commercial Application (2022-2030) ($MN)      
30 Global Vaccine Adjuvants Market Outlook, By End User (2022-2030) ($MN)      
31 Global Vaccine Adjuvants Market Outlook, By Human Vaccine Adjuvants (2022-2030) ($MN)      
32 Global Vaccine Adjuvants Market Outlook, By Veterinary Vaccine Adjuvants (2022-2030) ($MN)      
       
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.       

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials